Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for Janus kinases

被引:109
|
作者
Zhou, YJ
Chen, M
Cusack, NA
Kimmel, LH
Magnuson, KS
Boyd, JG
Lin, W
Roberts, JL
Lengi, A
Buckley, RH
Geahlen, RL
Candotti, F
Gadina, M
Changelian, PS
O'Shea, JJ [1 ]
机构
[1] NIAMSD, Lymphocyte Cell Biol Sect, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA
[2] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA
[3] Pfizer Inc, Global Res & Dev, Dept Immunol, Groton, CT 06340 USA
[4] Duke Univ, Sch Med, Dept Pediat, Durham, NC 27710 USA
[5] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
关键词
D O I
10.1016/S1097-2765(01)00398-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Janus kinases comprise carboxyterminal kinase, pseudokinase, SH2-like, and N-terminal FERM domains. We identified three patient-derived mutations in the FERM domain of Jak3 and investigated the functional consequences of these mutations. These mutations inhibited receptor binding and also abrogated kinase activity, suggesting interactions between the FERM and kinase domains. In fact, the domains were found to physically associate, and coexpression of the FERM domain enhanced activity of the isolated kinase domain. Conversely, staurosporine, which alters kinase domain structure, disrupted receptor binding, even though the catalytic activity of Jak3 is dispensable for receptor binding. Thus, the Jak FERM domain appears to have two critical functions: receptor interaction and maintenance of kinase integrity.
引用
收藏
页码:959 / 969
页数:11
相关论文
共 34 条
  • [1] Unexpected effects of N-terminal mutations on catalytic activity of JAK3: Structural implication for Janus kinases
    Zhou, YJ
    Changelian, PS
    O'Shea, JJ
    FASEB JOURNAL, 2001, 15 (05): : A1015 - A1015
  • [2] FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
    Elliott, Natalina E.
    Cleveland, Susan M.
    Grann, Victor
    Janik, John
    Waldmann, Thomas A.
    Dave, Utpal P.
    BLOOD, 2011, 118 (14) : 3911 - 3921
  • [3] JAK3 SCID: Mutations in noncatalytic domain and basis of Jak3 gamma c interaction.
    Chen, M
    Candotti, F
    Oakes, SA
    Vezzoni, P
    Blaese, RM
    Notarangelo, LD
    Villa, A
    OShea, JJ
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (01) : 1929 - 1929
  • [4] Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation
    Liu, KD
    Gaffen, SL
    Goldsmith, MA
    Greene, WC
    CURRENT BIOLOGY, 1997, 7 (11) : 817 - 826
  • [5] Jak3 kinase domain crystal structures and implication's for Jak-specific drug design.
    Boggon, TJ
    BLOOD, 2005, 106 (11) : 24A - 25A
  • [6] The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
    Saharinen, P
    Silvennoinen, O
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (49) : 47954 - 47963
  • [7] The transcription factor Ets-1 is essential for janus kinase 3 (Jak3) promoter activity
    Aringer, M
    Hofmann, S
    Frucht, DM
    Min, C
    Centola, M
    Morinobu, A
    Visconti, R
    Haleem-Smith, H
    Kastner, DL
    Smolen, JS
    O'Shea, JJ
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S346 - S346
  • [8] Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
    Chen, M
    Cheng, A
    Candotti, F
    Zhou, YJ
    Hymel, A
    Notarangelo, LD
    O'Shea, JJ
    FASEB JOURNAL, 1999, 13 (05): : A1145 - A1145
  • [9] Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
    Chen, M
    Cheng, A
    Candotti, F
    Zhou, YJ
    Hymel, A
    Fasth, A
    Notarangelo, LD
    O'Shea, JJ
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (03) : 947 - 956
  • [10] Ranked binding energies of residues and data fusion to identify the active and selective pyrimidine-based Janus kinases 3 (JAK3) inhibitors
    Gholamhoseinnia, M.
    Asadollahi-Baboli, M.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2022, 33 (01) : 23 - 34